2025
SJR Q2
JCR Q4 · 0,8
4 matched articles
Journal detail
Expert Opinion on Orphan Drugs
- Publisher
- Taylor and Francis Ltd.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
21678707
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,392
- Quartile Q2
- H-Index 30
- Cites/doc 4,75
- Docs (3y) 16
- Cites (3y) 41
Clarivate
Web of Science · JCR · 2023
- JCR Q Q4
- JIF 0,8
- 5Y JIF 0,7
- JCI 0,14
Subject classification
Categories (SJR)
- Health Policy Q3
- Pharmacology (medical) Q3
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous) Q2
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | — | 0,392 | — | — | — | — | 30 |
| 2024 | Q2 | — | 0,286 | — | — | — | — | 29 |
| 2023 | Q3 | Q4 | 0,199 | 0,8 | 0,7 | 0,14 | Q4 | 29 |
| 2022 | Q2 | Q4 | 0,238 | 0,8 | 0,7 | 0,12 | Q4 | 29 |
| 2021 | Q3 | Q4 | 0,222 | 1 | 0,8 | 0,15 | Q4 | 29 |
| 2020 | Q3 | Q4 | 0,237 | 0,7 | 0,8 | 0,14 | Q4 | 29 |
| 2019 | Q2 | Q4 | 0,311 | 0,8 | 0,7 | 0,17 | Q4 | 29 |
| 2018 | — | Q4 | — | 0,8 | 0,7 | 0,15 | Q4 | — |
| 2017 | Q2 | Q4 | 0,279 | 0,7 | 0,6 | 0,14 | Q4 | 29 |
| 2016 | Q2 | Q4 | 0,268 | 0,6 | 0,6 | — | — | 29 |
| 2015 | Q3 | Q4 | 0,213 | 0,5 | 0,5 | — | — | 29 |
| 2014 | Q3 | Q4 | 0,191 | 0,5 | 0,5 | — | — | 29 |
| 2013 | — | — | — | — | — | — | — | 29 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 311/354 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 261/278 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 262/279 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 266/276 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 258/271 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 247/267 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 244/261 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 247/257 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 244/255 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 237/255 |